Brazil allows trials of Chinese CoronaVac vaccine to resume

Brazil’s national health regulator allowed clinical trials of a Chinese-developed Covid-19 vaccine to resume on Wednesday, two days after suspending them in what critics called a decision tainted by politics.The regulatory agency, Anvisa, said it had now received more details on the nature of the “adverse incident” that led it to halt trials of Sinovac Biotech’s CoronaVac vaccine, and had “sufficient information to allow vaccination to resume.”Brazil spat over China vaccine is more about…

Read the original article at South China Morning Post